Patient 1 – “One hour later and I have all the feeling back in my mouth, that’s good stuff.”
Patient 2 – “Complained ahead of anesthesia that she typically stays numb for 6 hours or longer and hates being numb. So I offered her OraVerse to try. She called and said it was the best experience with anesthesia she has ever had. She said there is no way she will ever have a procedure done again without OraVerse and will gladly pay extra for the reversal of the anesthetic affects. She also reported instead of being numb for 6 hours or longer she was only numb for 2 hours.”
Patient 3 – “Oh my God this is the greatest stuff in the world. The numbness wore off in less than one hour. I would gladly pay for this treatment in the future.’’
So far after using OraVerse on three patients the feedback has been incredibly positive. There have been zero negative comments and patients have reported they would gladly pay extra for OraVerse. I can see this being a significant opportunity as a practice builder for a dentist, with OraVerse possibly separating one office from another.’’
What is OraVerse?
Ready. Set. Reverse!
It’s a whole new direction in
distinguishing your practice.
Safety & Efficacy
See the safety and efficacy
results from clinical trials as
well as clinical pharmacology.
OraVerse has been featured
and reviewed in leading
journals and publications.
OraVerse (Phentolamine Mesylate) injection is the first and only local dental anesthesia reversal agent.
OraVerse is indicated for the reversal of soft tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. It accelerates the return to normal sensation and function following restorative and periodontal maintenance procedures. In randomized, controlled clinical trials, the median time to recovery of normal sensation in the upper lip was 50 minutes for OraVerse patients vs 133 minutes for the control and in the lower lip was 70 minutes vs 155 minutes. Use in pediatric patients less than 3 years of age or <15 kg (33lbs) has not been established.
The most common adverse reaction with OraVerse is injection-site pain.
Important Safety Information
Tachycardia, bradycardia, and cardiac arrhythmias may occur with the use of phentolamine or other alpha-adrenergic blocking agents. Although such effects are uncommon with OraVerse (phentolamine mesylate), clinicians should be alert to the signs and symptoms of these events, particularly in patients with a history of cardiovascular disease. Following parenteral use of phentolamine at doses between 5 to 15 times higher than the recommended dose of OraVerse, myocardial infarction, and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states.